Skip to Content

News & Events

Press Releases

Press Releases

Date	Title and Summary	Additional Formats
Toggle SummarySep 9, 2005	Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated General Business	View HTML Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock 8.1 KB
Toggle SummaryAug 9, 2005	Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated General Business	View HTML Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock 8.2 KB
Toggle SummaryJul 27, 2005	Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. “Vertex’s progress in the second quarter of 2005 was General Business	View HTML Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results 403.6 KB
Toggle SummaryJul 26, 2005	Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis - Combination of Lexiva/r and Truvada Evaluated - General Business	View HTML Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis 15.3 KB
Toggle SummaryJul 26, 2005	Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy - Combination of Lexiva/r and Truvada Evaluated - General Business	View HTML Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy 15.3 KB
Toggle SummaryJul 19, 2005	FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385) - GlaxoSmithKline To Initiate Phase IIb Clinical Trial in HIV-infected Patients - General Business	View HTML FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385) 8.9 KB
Toggle SummaryJun 17, 2005	Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Whitehouse Station, NJ and Cambridge, MA, June 17, 2005 - Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of an additional Phase I Other	View HTML Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 14.3 KB
Toggle SummaryJun 15, 2005	Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters Cambridge, MA, June 15, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters have exercised in full their over-allotment option to purchase 1,762,500 shares of common stock General Business	View HTML Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters 7.5 KB
Toggle SummaryJun 13, 2005	Vertex Pharmaceuticals Announces Completion of Common Stock Offering Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, June 13, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offering of 11,750,000 shares of common stock. The gross proceeds, before commissions and expenses, of General Business	View HTML Vertex Pharmaceuticals Announces Completion of Common Stock Offering 7.5 KB
Toggle SummaryJun 10, 2005	Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Cambridge, MA, June 10, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of dosing in a Phase II clinical study in Other	View HTML Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 11.3 KB